<DOC>
	<DOCNO>NCT00163085</DOCNO>
	<brief_summary>To determine effect NMDA antagonist , CP-101,606 , subject Parkinson 's Disease</brief_summary>
	<brief_title>The Effects NR2B NMDA Antagonist , CP-101,606 , Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>30 80yearold PD patient ( UK Parkinson 's Disease Brain Bank criterion ) Hoehn &amp; Yahr stage score 25 `` '' state . Subjects evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>